LEVULAN KERASTICK 20 %
AMINOLEVULINIC ACID HYDROCHLORIDE : 20 % · DIN 02243933 · SUN PHARMACEUTICAL INDUSTRIES, INC.
Health Canada status: MARKETED
What is LEVULAN KERASTICK?
LEVULAN KERASTICK 20 % contains AMINOLEVULINIC ACID HYDROCHLORIDE : 20 %. It is listed in the Health Canada Drug Product Database under DIN 02243933, held by SUN PHARMACEUTICAL INDUSTRIES, INC., supplied as POWDER FOR SOLUTION for TOPICAL administration. Health Canada currently lists it as marketed, status dated 22-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LEVULAN KERASTICK used for?
Levulan Kerastick (aminolevulinic acid hydrochloride), with blue light irradiation, is indicated for the treatment of single and multiple non-hyperkeratotic actinic keratoses of the face and scalp.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243933 |
|---|---|
| Brand name | LEVULAN KERASTICK |
| Generic / active ingredient | AMINOLEVULINIC ACID HYDROCHLORIDE : 20 % |
| Manufacturer | SUN PHARMACEUTICAL INDUSTRIES, INC. |
| Strength | 20 % |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | L01XD04 AMINOLEVULINIC ACID |
| AHFS class | 84:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Jul-2025 |
| Original market date | 2004-06-03 00:00:00 |
How is it stored and handled?
null
How is it supplied?
6 applicators
What can be used instead?
Other Canadian products sharing ATC code L01XD04 AMINOLEVULINIC ACID. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GLEOLAN | 1.5 G | POWDER FOR SOLUTION | MEDEXUS PHARMACEUTICALS INC. | MARKETED | DIN 02504928 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.